Surgery (partial or gross total resection or biopsy) must be performed >= 2 weeks prior to registration; patient must have recovered adequately from the effects of surgery
360.0
Patients must not have had major surgery within 6 weeks prior to enrollment on the high risk stratum; patients with history of recent minor surgical procedures (vascular catheter placement, bone marrow evaluation, laparoscopic surgery, liver tumor biopsy) will be eligible
253.0
Patients should not be randomized less than 3 weeks post-surgery but will not be acceptable for randomization more than 8 weeks post-surgery
360.0
Patients must not have had a previous surgical resection; however, patients may have undergone exploratory thoracotomy, mediastinoscopy, excisional biopsy or similar surgery for the purpose of determining the diagnosis, stage or potential resectability of newly diagnosed lung tumor; at least 28 days must have elapsed since thoracic surgery (excluding mediastinoscopy or other minor surgeries) and patients should have recovered from all associated toxicities at the time of registration; patients must not be planning to undergo a minor surgical procedure while on this study
162.0
Previous radical surgery (prostatectomy) or cryosurgery for prostate cancer
2580.0
Bilateral mammogram =< 90 days prior to date of surgery; Note: for patients undergoing more than 1 breast operation, this is the date of the first breast surgery for breast cancer treatment
265.0
Lumbar CSF must be obtained prior to study enrollment unless medically contraindicated; if a patient undergoes surgery and lumbar CSF cannot be obtained at this time, then it should be performed at least 10 days following surgery before study enrollment; false positive cytology can occur within 10 days of surgery; Note: patients with positive CSF cytology obtained prior to 10 days after surgery may have cytology repeated to determine eligibility
275.0
Patient must consent for the appropriate surgery
600.0
The patient must have recovered from surgery with the incision completely healed and no signs of infection
1636.0
Patients with microscopic positive margins after definitive surgery
1636.0
Patients with residual macroscopic disease after surgery
252.0
Patients may have received prior surgery (for both the primary and stage IV disease); all adverse events associated with prior surgery must have resolved to =< grade 1 prior to registration
97.0
Recent major surgery within a minimum of 4 weeks prior to starting study treatment, with the exception of surgical placement for vascular access
104.0
Major surgery within 4 weeks prior to entry into the study, or a surgical incision that is not fully healed
70.0
Patients who have received any cytotoxic therapy, immunotherapy, antitumor vaccines, monoclonal antibodies or major surgery in the 4 weeks prior to the start of the study
52.0
Have surgery planned within 3 months of consent; patients who have previously received surgery are eligible
700.0
Patients who are not currently candidates for radical cystectomy (e.g. patient refuses surgery, comorbidities preclude major surgery, etc.)
54.0
Patient must have fully recovered from the effects of prior surgery at least 14 days prior to sub-study registration
10000.0
At least 4 weeks must have elapsed since the patient underwent any major surgery (eg. MAJOR: laparotomy, laparoscopy, thoracotomy, VATS [video assisted thorascopic surgery]); there is no restriction on MINOR procedures: (eg. central venous catheter placement, ureteral stent placement or exchange, tumor core or fine-needle aspirate [FNA] biopsy)
250.0
Major surgery within 2 weeks prior to randomization: patients must have recovered from any effects of any major surgery
1500.0
Prior surgery for the IHC; (liver resection is not allowed)
182.0
The patient must have recovered from effects of surgery, postoperative infection, and other complications within 28 days prior to step 2 registration
606.0
Patients must be adequately recovered from surgery at the time of randomization
NONE
Patients must have discontinued radiation therapy prior to registering to Step 2 of the study and recovered from any adverse events associated with treatment; prior surgery must be >= 2 weeks from registration to Step 2 and patients must be fully recovered from post-surgical complications
300.0
Major surgery within 4 weeks of first dose of study drug
52.0
Patients who are less than 4 weeks post-operative (op) after major surgery
36.0
No clinically significant bleeding (i.e. gastrointestinal [GI] bleed, intracranial bleeding) within 6 months or major surgery within 4 weeks; minor surgeries (i.e. port placement, cataract surgery) are allowed within 2 weeks
66.0
Have had recent major surgery within a minimum of 4 weeks prior to starting study treatment, with the exception of surgical placement for vascular access
50.0
Patients, who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that may require major surgery during the course of the study
50.0
Patients may have received prior surgery; at least 28 days must have elapsed since surgery and patient must have recovered from any adverse effects of surgery
180.0
Patients must not have any unresolved wounds from previous surgery
180.0
Ibrutinib should be held at least 3 to 7 days pre- and post-surgery, depending upon the type of surgery and risk of bleeding
32.0
At least 4 weeks since major surgery or radiation therapy
70.0
Inability to safely delay surgery by 8 weeks as per surgeon�s discretion
29.0
No prior bariatric surgery or planning to undergo this procedure within the next 2 years after study registration
NONE
PRIOR/CONCURRENT THERAPY CRITERIA: Patients must not have had a major surgery within 28 days prior to registration; patients must have recovered from any adverse effects of prior surgery to the satisfaction of the treating physician; biopsies and central IV access placement are not considered major surgery
53.0
Patients must be enrolled on ALTE07C1 prior to enrollment on ACNS1422* Patients must be enrolled within 36 days of definitive diagnostic surgery (day 0)** Note: patients must begin treatment within 36 days of definitive surgery
45.0
Patients who are not candidates for major abdominal surgery due to known medical comorbidities
147.0
Major surgery within 4 weeks before randomization
348.0
Patients must have recovered from effects of recent surgery, radiotherapy, or chemotherapy; at least 4 weeks must have elapsed since the patient underwent any major surgery (e.g., major: laparotomy, laparoscopy); there is no delay required for minor procedures (e.g., tumor fine-needle aspiration [FNA] or core biopsy, venous access device placement)
84.0
Patients must have fully recovered from any adverse effects of major surgery (to =< grade 1) at least 14 days prior to registration
707.0
Have had recent major surgery within a minimum of 4 weeks prior to starting study treatment, with the exception of surgical placement for vascular access
24.0
Major surgical procedure (as defined by the investigator) within 28 days prior to the first dose of IP; Note: local surgery of isolated lesions for palliative intent is acceptable
180.0
Patients must NOT have radiotherapy, or major surgery or active drug therapy for pNET (SSA permitted) within 4 weeks prior to study treatment start
40.0
Patients who have had major surgery or trauma within 28 days prior to entering the study; patients must have recovered from any effects of any major surgery and surgical wound should have healed prior to starting treatment
132.0
Step 1 registration must occur within 180 days of the initial surgery; within this 180 day interval, a second surgery is permitted in order to achieve GTR, but even with a second surgery, step 1 registration must occur within 180 days of the initial resection
148.0
Major surgery must not have occurred within 2 weeks prior to enrollment and patients must have recovered from any effects of any major surgery
49.0